Skip to main content

United States News All stories

Every story in this section, newest first — page 249 of 373.

Grafa
Health

Cellectis reports 100% ORR for Lasme-cel as $211M cash runway extends into 2027

Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its proprietary TALEN® gene-editing platform to develop next-generation immunotherapies, announced its financial and operational results for the fiscal year ended December 31, 2025.

Read more: Cellectis reports 100% ORR for Lasme-cel as $211M cash runway extends into 2027
Grafa
Mining

US Antimony revenues surge 163% as critical mineral demand drives $354M in new contracts

United States Antimony (NYSE:UAMY) announced its financial results for the fiscal year ended December 31, 2025, reporting a period of exponential top-line growth driven by the tightening global supply of critical minerals.

Read more: US Antimony revenues surge 163% as critical mineral demand drives $354M in new contracts
Grafa
Energy

SOLV Energy post-IPO backlog surges 87% to $8B as 2026 revenue targets top $3.7B

SOLV Energy (NASDAQ:MWH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, marking its first earnings report as a public company following its successful Nasdaq debut in February 2026.

Read more: SOLV Energy post-IPO backlog surges 87% to $8B as 2026 revenue targets top $3.7B